Recurrent Glioblastoma

Showing 1 - 25 of 97

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent Glioblastoma Trial in Brussels (Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV,

Not yet recruiting
  • Recurrent Glioblastoma
  • Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
  • +2 more
  • Brussels, Belgium
    UZ Brussel
Oct 23, 2023

Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma Trial in Los Angeles (Biospecimen Collection, Magnetic Resonance

Recruiting
  • Glioblastoma
  • +2 more
  • Biospecimen Collection
  • +2 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 13, 2023

Recurrent Glioblastoma Trial (Atezolizumab)

Not yet recruiting
  • Recurrent Glioblastoma
  • (no location specified)
Oct 3, 2023

Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)

Recruiting
  • Brain Cancer
  • +4 more
  • Trastuzumab deruxtecan
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023

Recurrent Glioblastoma, Glioblastoma Multiforme, GBM Trial in Charlottesville (5-ALA and Low-Intensity Focused Ultrasound (SDT))

Not yet recruiting
  • Recurrent Glioblastoma
  • +2 more
  • 5-ALA and Low-Intensity Focused Ultrasound (SDT)
  • Charlottesville, Virginia
    University of Virginia
Sep 10, 2023

Glioblastoma Multiforme, Adult, Recurrent Glioblastoma Trial in Rotterdam (Pitavastatin calcium)

Not yet recruiting
  • Glioblastoma Multiforme, Adult
  • Recurrent Glioblastoma
  • Pitavastatin calcium
  • Rotterdam, Netherlands
    Erasmus MC
Aug 3, 2023

Recurrent Glioblastoma Trial in Portland (TVI-Brain 1)

Available
  • Recurrent Glioblastoma
  • TVI-Brain 1
  • Portland, Oregon
    Providence St. Vincent Medical Center
Jun 28, 2023

Glioblastoma, Recurrent Glioblastoma, GBM Trial in Worldwide (SonoCloud-9 (SC9), Carboplatin, Lomustine)

Not yet recruiting
  • Glioblastoma
  • +2 more
  • SonoCloud-9 (SC9)
  • +3 more
  • Chicago, Illinois
  • +7 more
Jun 5, 2023

Recurrent Glioblastoma Trial in Houston (Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab)

Not yet recruiting
  • Recurrent Glioblastoma
  • Houston, Texas
    M D Anderson Cancer Center
May 18, 2023

Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

Not yet recruiting
  • Recurrent Glioblastoma
  • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
  • (no location specified)
Apr 4, 2023

Glioblastoma, Recurrent Glioblastoma Trial in Atlanta (Avutometinib, Biospecimen Collection, Defactinib)

Not yet recruiting
  • Glioblastoma
  • Recurrent Glioblastoma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Mar 22, 2023

Recurrent Glioblastoma Trial in Jacksonville (Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma
  • Allogeneic Adipose-derived Mesenchymal Stem Cells
  • +4 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 16, 2023

Recurrent High-grade Glioma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma Trial in Incheon (500mg/kg/3hr followed by

Recruiting
  • Recurrent High-grade Glioma
  • +3 more
  • 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq
  • +2 more
  • Incheon, Korea, Republic of
    Gachon University Gil Medical Center
Feb 19, 2023

Recurrent Glioblastoma Trial (fractionated radiotherapy, cadonilimab)

Not yet recruiting
  • Recurrent Glioblastoma
  • (no location specified)
Feb 20, 2023

Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma Trial in United States (biological, procedure, radiation)

Suspended
  • Diffuse Astrocytoma, IDH-Wildtype
  • Recurrent Glioblastoma
  • Atezolizumab
  • +5 more
  • Los Angeles, California
  • +73 more
Jan 31, 2023

Recurrent Glioblastoma Trial (MTX110, Programmable pump and catheter system, Lomustine)

Recruiting
  • Recurrent Glioblastoma
  • Jacksonville, Florida
  • +1 more
Jan 26, 2023

Glioblastoma, Recurrent Glioblastoma Trial in United States (ASP8374, cemiplimab)

Active, not recruiting
  • Glioblastoma
  • Recurrent Glioblastoma
  • Boston, Massachusetts
  • +3 more
Jan 13, 2023

Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (other, biological, procedure)

Active, not recruiting
  • Recurrent Glioblastoma
  • Recurrent Gliosarcoma
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 19, 2022

Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Rochester (Laboratory Biomarker Analysis,

Active, not recruiting
  • Giant Cell Glioblastoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Jan 4, 2023

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • Hangzhou, Zhejiang, China
  • +2 more
Dec 25, 2022

Recurrent Glioblastoma Trial (Niraparib, Re-irradiation (re-RT))

Not yet recruiting
  • Recurrent Glioblastoma
  • (no location specified)
Dec 23, 2022

Recurrent Glioblastoma Trial in Beijing (Laser interstitial thermal therapy, Temozolomide)

Active, not recruiting
  • Recurrent Glioblastoma
  • Beijing, China
    Beijing Tiantan Hospital
Dec 22, 2022

Glioblastoma, Malignant Glioma, Recurrent Glioblastoma Trial in Boston (CARv3-TEAM-E T cells)

Not yet recruiting
  • Glioblastoma
  • +3 more
  • CARv3-TEAM-E T cells
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Dec 13, 2022

Recurrent Glioblastoma Trial (Sintilimab plus Bevacizumab and Temozolomide)

Not yet recruiting
  • Recurrent Glioblastoma
  • Sintilimab plus Bevacizumab and Temozolomide
  • (no location specified)
Nov 27, 2022

Glioblastoma, Recurrent Glioblastoma Trial in San Francisco (RMC-5552)

Not yet recruiting
  • Glioblastoma
  • Recurrent Glioblastoma
  • San Francisco, California
    University of California, San Francisco
Nov 28, 2022